Saiful Azmi Johari1*, Mohd Kamal Nik Hasan1, Mastura Mohtar1, Azman Mohamed1, Mazurah Mohamed Isa1, Hanan Abdul Wahab1, Mohd Fazli Mohammat2
1. Antimicrobial Laboratory & Cell Signalling and In Vivo Laboratory Bioactivity Programme, Natural Products Division, Forest Research Institute Malaysia, 52109 Kepong, Selangor, Malaysia
2. Centre for Chemical Synthesis & Polymer Technology, Institute of Science, Universiti Teknologi MARA, Puncak Alam Campuses, Bandar Puncak Alam, 42300 Kuala Selangor, Selangor, Malaysia
*Corresponding author: Saiful Azmi Johari.
ABSTRACT
INTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) has been known to display multidrug-resistance properties towards a wide range of structurally unrelated antimicrobial agents. Currently, only a handful of antibiotics can inhibit this dangerous nosocomial pathogen. Thus, a dire need for an alternative source of antimicrobials is crucial to reduce MRSA infections worldwide. Previously, HCD1 showed good antibacterial activity with minimum inhibitory concentration (MIC) values of < 8 µg/mL against 90 MRSA and 20 methicillin-susceptible Staphylococcus aureus (MSSA) isolates.
OBJECTIVE(S): This study was carried out to determine the antibacterial, safety, and efficacy properties of HCD1 using various in vitro and in vivo models.
MATERIALS & METHODS: In vitro time-kill, single-step FOR assay and cytotoxicity studies were carried out against HCD1. Next, in vivo acute and sub-acute toxicity using Sprague-Dawley (SD) rats was conducted as per the Organisation for Economic Co-operation and Development (OECD) 420 and 407 guidelines, respectively. Additionally, the survival rate and mean effective dose (ED50) of HCD1 against MRSA systemic infection in ICR mice were determined. Lastly, gene expression of an MRSA isolate exposed to HCD1 was also analysed.
RESULTS: HCD1 showed a bactericidal effect in the time-kill assay and displayed a low toxicity with IC50 values of > 300 µg/mL against two normal cell lines. No resistant MRSA mutants were detected in the FOR assay (up to 16x MIC values). No mortality or behavioural changes were observed in SD rats treated with a single dose of 2000 mg/kg and repeated doses of 125 mg/kg of HCD1 in acute and sub-acute toxicity evaluations, respectively. HCD1 provided an 83% survival rate in MRSA-infected mice with an ED50 calculated at 38.76 mg/kg. Transcriptomic analysis revealed that HCD1 may disrupt MRSA survival by repressing its energy production, hence abolishing the regulation of various important transmembrane transporters and the formation of biofilm in the cell.
CONCLUSION: HCD1 is highly recommended to be developed further as a safe and efficacious novel antibiotic against MRSA.
KEYWORDS: MRSA, Novel Antibiotic, Toxicity, Animal Model, Systemic Infection


